Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a chinese population

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 357-364

  Fang, Yiru ^a   Yuan, Chengmei ^a   Xu, Yifeng ^a   Chen, Jun ^a   Wu, Zhiguo ^a   Cao, Lan ^a   Yi, Zhenghui ^a   Hong, Wu ^a   Wang, Yong ^a   Jiang, Kaida ^a   Gao, Keming ^b   Cui, Xingjia ^c   Nierenberg, Andrew A ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

extended release venlafaxine; mirtazapine; paroxetine; switch strategies; treatment resistant depression

Indexed keywords

ANXIOLYTIC AGENT; BUSPIRONE; HYPNOTIC SEDATIVE AGENT; MIRTAZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; DELAYED RELEASE FORMULATION; MIANSERIN;

ADULT; ANOREXIA; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; CHINA; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; MIDDLE AGED; PILOT STUDY; PROCEDURES; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHINA; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77955173634     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e7784f     Document Type: Article

References (41)

1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53:849-857.
2. Lu J, Ruan Y, Huang Y, et al. Major depression in Kunming: prevalence, correlates and co-morbidity in a south-western city of China. J Affect Disord. 2008;111:221-226.
3. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19: 179-200.
4. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
5. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221-225.
6. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-753.
7. Malhi GS, Parker GB, Crawford J, et al. Treatment-resistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112:302-309.
8. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(suppl 8):5-12.
9. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29.
10. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9: 808-821.
11. Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62:22-29.
12. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003;160:237.
13. Posternak MA, Zimmerman M. The effectiveness of switching antidepressants during remission: a case series of depressed patients who experienced intolerable effects. J Affect Disord. 2002;69:237-240.
14. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11.
15. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17.
16. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531-1541.
17. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161-1172.
18. Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry. 2005;66:670-676.
19. Jain R. Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 1):7-11.
20. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-239.
21. Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004;65(suppl 17):11-18.
22. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
23. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
24. Fava M, Dunner L, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62:413-420.
25. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison. Br J Psychiatry. 1999;175:12-16.
26. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009;259(3):172-185.
27. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64:1065-1074.
28. Gao XH. [Analysis of the antidepressants use in a hospital]. J Lanzhou Univ Med Sci. 2006;32:73-74.
29. Trivedi MH, Pigotti TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:1356-1364.
30. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42-56.
31. Zheng YP, Zhao JP, Phillips M, et al. Validity and reliability of the Chinese Hamilton Depression Rating Scale. Br J Psychiatry. 1988;152:660-664.
32. Zhang MY. [Manual for Psychiatric Rating Scale]. 1st ed. Changsha: Hunan Science and Technology Press; 1998.
33. Wu WY. [Clinical Global Impression (CGI)]. Shanghai Archives of Psychiatry. 1984;2:24-25.
34. Cheng JJ, Ho H, Chang CJ, et al. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Chinese Psychiatry. 1996;10:251-258.
35. Wang XD. [Manual for psychological rating scale]. Chinese Mental Health Journal. 1999;(suppl 131-133):76-78.
36. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869-877.
37. Hirschfeld RA. The use of mirtazapine in difficult-to-treat patient populations. Hum Psychopharmacol Clin Exp. 2002;17:S33-S36.
38. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine-Venlafaxine Study Group: mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21:425-431.
39. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv. 1998;49:239-240.
40. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment responseVan association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry. 2008;63:1103-1110.
41. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.